Vedolizumab bulk supplier for pharma manufacturers

Vedolizumab 300mg, 108 mg/0.68 mL Suppliers & Bulk Manufacturers

Available Forms: Injection / infusion

Available Strengths: 300mg, 108 mg/0.68 mL

Reference Brands: ENTYVIO (USA/EU)

Vedolizumab is a gut-selective monoclonal antibody that blocks the α4β7 integrin, preventing white blood cells from migrating into inflamed gastrointestinal tissue. It is used to treat adults with moderate to severe ulcerative colitis or Crohn’s disease who have not responded adequately to conventional therapies. Entyvio is administered either as an intravenous infusion (300 mg) or subcutaneous injection (108 mg). The drug is known for its targeted mechanism that reduces systemic immunosuppression compared to other biologics.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Vedolizumab? List it or send an offer →

Product Description:

Vedolizumab is a humanised monoclonal antibody against alpha4-beta7 integrin, found on a subset of lymphocytes that home to the gut. Alpha4-beta7 binds MAdCAM-1, a receptor expressed on blood vessels in the gut mucosa. Blocking that interaction stops inflammatory lymphocytes from entering intestinal tissue, while leaving immune surveillance elsewhere largely intact. That gut selectivity is the drug's defining feature and underlies its safety profile.

It is used for moderate to severe ulcerative colitis and Crohn's disease in adults. Induction is by intravenous infusion, followed by maintenance infusions every eight weeks or subcutaneous self-injection every two weeks. Response can be slower than with anti-TNF drugs, particularly in Crohn's disease. Systemic infection risk is lower than with broader immunosuppressants, and — unlike natalizumab, which blocks a wider integrin — progressive multifocal leukoencephalopathy has not been linked to it. Infusion reactions, nasopharyngitis, headache and arthralgia are common.

Sourcing notes. Originator biologic. Biosimilar applications are under review in the US and EU, but none has yet been approved, so for now supply is originator only, through authorised distribution under cold chain. The intravenous vial and the subcutaneous pen are separate presentations. Biosimilar entry will change pricing in the next few years.

How Vedolizumab is supplied today, and licensing ahead of patent expiry

Vedolizumab is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Vedolizumab, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Vedolizumab supply →

Back to Listing

Frequently Asked Questions

Vedolizumab is used to treat moderate to severe ulcerative colitis and Crohn’s disease in adults. It helps reduce inflammation in the digestive tract and maintain remission by blocking the movement of inflammatory white blood cells (lymphocytes) into the gut, which are responsible for causing inflammation.

Vedolizumab is made from Vedolizumab, a humanized monoclonal antibody that targets the α4β7 integrin receptor on gut-specific lymphocytes, thereby preventing their migration to inflamed intestinal tissue.

The trade name of Vedolizumab is Entyvio.

Vedolizumab (En tyvio)is developed and manufactured by Takeda Pharmaceutical Company Limited, Japan, and marketed globally under regulatory approvals.

The generic name of Vedolizumab is Vedolizumab.

The brand name of Vedolizumab is Entyvio.

Vedolizumab is manufactured by Takeda Pharmaceutical Company in Japan and its production facilities in the United States and Europe under strict GMP guidelines.

Entyvio (Vedolizumab) is developed and sold by Takeda. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.